

Annex 1

Drugs covered by SF in 2009-10	Number of applications approved			Average amount of subsidy of each case approved (\$)	Average amount of patients' contribution of each case approved for partial subsidy (\$)	Total amount of subsidy approved (\$million)
	Full subsidy	Partial subsidy	Total			
1 Interferon:	91	32	123	42,470	5,850	5.22
2 Cetuximab:	8	1	9	81,464	23,832	0.73
3 Etanercept:	71	28	99	60,923	10,876	6.03
4 Infliximab:	81	49	130	76,459	10,825	9.94
5 Oxaliplatin:	20	11	31	28,473	11,237	0.88
6 Rituximab:	70	53	123	71,806	21,694	8.83
7 Trastuzumab:	86	49	135	72,388	34,415	9.77
8 Imatinib (i.e. Glivec):	161	142	303	135,898	26,070	41.18
9 Irinotecan (Campto):	118	24	142	11,165	3,662	1.59
10 Growth hormone	0	0	0	N.A.	N.A.	N.A.
Total	706	389	1095	76,874	20,040	84.18

Note: Cetuximab and Oxaliplatin were introduced into the coverage of SF in 2009-10. Irinotecan (Campto) was included in the HA Drug Formulary as Special Drug in 2010-11.

Drugs covered by SF in 2010-11	Number of applications approved			Average amount of subsidy of each case approved (\$)	Average amount of patients' contribution of each case approved for partial subsidy (\$)	Total amount of subsidy approved (\$million)
	Full subsidy	Partial subsidy	Total			
1 Interferon:	37	16	53	86,169	11,233	4.57
2 Adalimumab:	21	14	35	98,113	12,395	3.43
3 Bortezomib:	20	15	35	131,601	30,212	4.61
4 Cetuximab:	14	9	23	70,328	5,728	1.62
5 Dasatinib:	6	6	12	248,629	15,384	2.98
6 Etanercept:	109	40	149	64,632	16,261	9.63
7 Infliximab:	75	47	122	106,167	11,618	12.95
8 Nilotinib:	14	22	36	263,472	29,502	9.48
9 Oxaliplatin:	44	30	74	30,265	13,007	2.24
10 Pemetrexed:	1	1	2	97,495	6,250	0.19
11 Rituximab:	91	81	172	72,479	29,302	12.47
12 Trastuzumab:	132	178	310	128,565	50,253	39.86
13 Imatinib (i.e. Glivec):	164	167	331	140,515	34,483	46.51
14 Growth hormone	0	0	0	N.A.	N.A.	N.A.
Total	728	626	1354	111,183	32,379	150.54

Note: Adalimumab, Bortezomib, Dasatinib, Nilotinib and Pemetrexed were introduced into the coverage of SF in 2010-11.

Drugs covered by SF in 2011-12	Number of applications approved			Average amount of subsidy of each case approved (\$)	Average amount of patients' contribution of each case approved for partial subsidy (\$)	Total amount of subsidy approved (\$million)
	Full subsidy	Partial subsidy	Total			
1 Interferon:	40	17	57	85,990	11,799	4.90
2 Adalimumab:	57	28	85	109,941	14,841	9.35
3 Bortezomib:	38	14	52	173,679	34,024	9.03
4 Cetuximab:	16	5	21	74,877	9,212	1.57
5 Dasatinib:	20	8	28	229,320	35,056	6.42
6 Etanercept:	129	47	176	63,773	16,027	11.22
7 Erlotinib:	12	8	20	146,559	24,126	2.93
8 Gefitinib:	23	14	37	145,276	32,427	5.38
9 Infliximab:	68	29	97	101,142	8,277	9.81
10 Nilotinib:	23	17	40	242,704	33,206	9.71
11 Oxaliplatin:	47	24	71	18,896	5,102	1.34
12 Pemetrexed:	2	2	4	65,445	22,045	0.26
13 Rituximab:	86	95	181	70,294	32,378	12.72
14 Temozolomide:	2	4	6	50,709	45,180	0.30
15 Trastuzumab:	123	165	288	127,367	48,188	36.68
16 Imatinib (i.e. Glivec):	187	166	353	150,879	29,958	53.26
17 Growth hormone	0	0	0	N.A.	N.A.	N.A.
Total	873	643	1516	115,365	31,059	174.89

Note: Erlotinib, Gefitinib and Temozolomide were introduced into the coverage of SF in 2011-12.